Complete financial analysis of AzurRx BioPharma, Inc. (AZRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AzurRx BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Roadman Investments Corp. (LITT.V) Income Statement Analysis – Financial Results
- Guoguang Electric Company Limited (002045.SZ) Income Statement Analysis – Financial Results
- Modern Living Investments Holdings Limited (8426.HK) Income Statement Analysis – Financial Results
- Oriental Chain Mfg. Co., Ltd. (6380.T) Income Statement Analysis – Financial Results
- Berenson Acquisition Corp. I (BACA-UN) Income Statement Analysis – Financial Results
AzurRx BioPharma, Inc. (AZRX)
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5,888.00B | 8.68M | 4.99M | 2.40M | 2.50M | 1.40M |
| General & Administrative | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20,544.76B | 0.00 | 210.00K | 7.69M | 4.13M | -4.73M |
| Operating Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | -3.33M |
| Cost & Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | 4.73M |
| Interest Income | 484.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5,840.61B | 433.94K | 101.85K | 875.20K | 5.94M | 1.59M |
| Depreciation & Amortization | 37.80K | 1.02M | 798.45K | 754.00K | 734.50K | 733.60K |
| EBITDA | -26,830.85B | -13.72M | -12.63M | -9.47M | -7.92M | -3.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26,432.77B | -14.74M | -13.43M | -10.08M | -6.63M | -4.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6,238.70B | -433.94K | -101.85K | -1.02M | -7.97M | -1.20M |
| Income Before Tax | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -398.08B | 0.00 | 0.00 | -140.00K | -2.03M | 386.11K |
| Net Income | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| EPS Diluted | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| Weighted Avg Shares Out | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
| Weighted Avg Shares Out (Dil) | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
3 Penny Stocks That Top Investors Buying Right Now
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma Announces Reverse Stock Split
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Source: https://incomestatements.info
Category: Stock Reports